SNWV — SANUWAVE Health, Inc.

Summary of SANUWAVE (SNWV) Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q1 2026 revenue reached $9.6 million, a 3% increase from $9.3 million in Q1 2025, marking the highest Q1 revenue in company history.
• Gross Margin: Gross margin was 77.3%, down 177 basis points year-over-year, primarily due to wholesale pricing impacts from increased sales through resellers.
• Operating Loss: The operating loss was $1.1 million, a significant decline from an operating income of $0.6 million in Q1 2025.
• Net Loss: Net loss improved to $1.4 million from $6.1 million year-over-year, largely due to the absence of a prior noncash loss related to derivative liabilities.
• Adjusted EBITDA: Adjusted EBITDA was positive at $1.1 million, down from $2.3 million in the previous year.
• Active Systems: The number of active systems increased to 1,382 from 1,292 at year-end, with a net change of +90 systems in Q1.

2. Strategic Updates and Business Highlights

• The company sold 97 systems in Q1, with a record in applicator unit sales, although revenue was affected by wholesale pricing.
• There is renewed interest in long-term care and nursing facilities for wound care, alongside strong performance in hospitals.
• SANUWAVE is focusing on mobile wound care, emphasizing its importance despite market misconceptions about its decline.
• The company is actively engaging with larger healthcare systems, which could lead to significant growth opportunities.

3. Forward Guidance and Outlook

• SANUWAVE expects Q2 2026 revenue growth of 10% to 15%, projecting revenues between $11.1 million and $11.6 million.
• The full-year revenue guidance remains unchanged at $51 million to $55 million, with optimism for stronger performance in the second half of the year based on historical seasonal trends and increased engagement with large accounts.

4. Bad News, Challenges, or Points of Concern

• The first month of Q1 experienced a significant market freeze due to unexpected CMS pricing changes, leading to elevated churn rates among practitioners.
• Operating expenses rose to $8.6 million, up from $6.8 million, driven by increased headcount, R&D investments, and nonrecurring expenses.
• Concerns about the sustainability of mobile wound care in rural areas due to lower pay rates and the need for reindexing travel reimbursements were highlighted.

5. Notable Q&A Insights

• Management expressed confidence in the second half of 2026, citing historical seasonal trends and increased engagement with large healthcare systems.
• There are ongoing advancements in the UltraMIST product and plans for evidence-based trials to support market expansion.
• The company is working on generating data to validate additional use cases for UltraMIST, with expectations for future publications to outline these findings.

Overall, SANUWAVE reported a mixed quarter with record revenues but faced challenges related to pricing and operating expenses. The outlook remains cautiously optimistic, with strategic initiatives aimed at expanding market presence and product utilization.